本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 健康元药业集团股份有限公司（以下简称：公司）于 2025 年 09 月 19 日（星期五）下 午 15:00-17:00 在上海证券交易所上证路演中心（网址：http://roadshow.sseinfo.com/），以 视频与网络文字互动方式召开了 2025 年半年度业绩说明会，针对公司 2025 年半年度的经 营成果及财务指标等具体情况与投资者进行互动交流和沟通，在信息披露允许的范围内就 投资者普遍关注的问题进行现场回复，现就有关情况公告如下： 一、本次说明会召开情况 健康元药业集团 关于2025年半年度业绩说明会召开情况的公告 证券代码：600380 证券简称：健康元 公告编号：临 2025-066 健康元药业集团股份有限公司 关于 2025 年半年度业绩说明会召开情况的公告 2025 年 09 月 19 日（星期五）下午 15:00-17:00，公司在上海证券交易所上证路演中心 召开 2025 年半年度业绩说明会，公司董事长朱保国先生，董事、总裁林楠棋先生，董事、 副总裁 ...

Core Viewpoint - As of September 18, a total of 149 stocks in the Shanghai and Shenzhen markets have experienced net buying from major funds for five consecutive days or more, indicating strong investor interest in these stocks [1] Group 1: Stocks with Significant Net Buying - The stock with the highest number of consecutive days of net buying is Tianpu Co., which has seen net buying for 13 consecutive trading days [1] - Other notable stocks with significant net buying days include Jiankangyuan, Shandong Publishing, Aima Technology, Mosi Co., Hunan Haili, Xiamen Guomao, Zhuojin Co., and Botuo Biotechnology [1]

Core Insights - As of September 17, a total of 98 stocks in the Shanghai and Shenzhen markets have experienced net buying from major funds for five consecutive days or more [1] - The stock with the longest streak of net buying is Haotaitai, which has seen net purchases for 15 consecutive trading days [1] - Other notable stocks with significant net buying days include Tianpu Co., Health元, Shandong Publishing, Mousse Co., Aima Technology, Hunan Haili, Baida Group, and Huadian New Energy [1]

瑞财经 钟鸣辰丽珠集团(SZ000513)近日发布2025年半年报，上半年同比增利不增收。 | | | | 单位:人民币元 | | --- | --- | --- | --- | | 项目 | 本期 | 上期 | 本期比上期增减 | | 营业收入 | 6,271.912,644.11 | 6.282.354.251.22 | -0.17% | | 归属于本公司股东的净利润 | 1,281,087,956.53 | 1,170,970,883.51 | 9.40% | | 归属于本公司股东的扣除非经常性损益 的净利润 | 1.258.455.473.79 | 1,155,469,307.79 | 8.91% | | 经营活动产生的现金流量净额 | 1.686.940.768.20 | 1,530,031,256.39 | 10.26% | | 基本每股收益(人民币元/股) | 1.43 | 1.27 | 12.60% | | 稀释每股收益(人民币元/股) | 1.43 | 1.27 | 12.60% | | 加权平均净资产收益率 | 9.14% | 8.04% | 增加 1.10个百分点 | | 项目 | 期末 ...

Core Insights - A total of 111 stocks in the Shanghai and Shenzhen markets have received net buying from major funds for five consecutive days or more as of September 16 [1] - The stock with the longest consecutive net buying days is Haotaitai, which has seen net buying for 14 consecutive trading days [1] - Other notable stocks with significant net buying days include Tianpu Co., CNOOC Engineering, Jianfeng Group, Jiankangyuan, Xingrong Environment, Shandong Publishing, Pudong Construction, and Hunan Haili [1]

Core Viewpoint - Health元's stock price has shown fluctuations, with a year-to-date increase of 15.36% but a recent decline in the last five trading days by 3.18% [1] Group 1: Financial Performance - For the first half of 2025, Health元 reported operating revenue of 7.898 billion yuan, a year-on-year decrease of 4.08%, while net profit attributable to shareholders increased by 1.10% to 785 million yuan [2] - Cumulative cash dividends since the A-share listing amount to 3.979 billion yuan, with 1.04 billion yuan distributed in the last three years [3] Group 2: Stock and Market Activity - As of September 16, Health元's stock price was 12.77 yuan per share, with a total market capitalization of 23.362 billion yuan [1] - The stock experienced a net outflow of 17.5091 million yuan from main funds, with significant selling pressure observed [1] Group 3: Shareholder Structure - As of June 30, 2025, Health元 had 76,300 shareholders, a decrease of 4.32% from the previous period, with an average of 23,991 circulating shares per shareholder, an increase of 4.52% [2] - The top circulating shareholder is Hong Kong Central Clearing Limited, holding 68.3785 million shares, an increase of 14.9969 million shares from the previous period [3]

Core Insights - The asthma market in China is experiencing significant growth, with the respiratory drug market size projected to reach approximately $12.8 billion in 2024, up from $11.8 billion in 2023, driven by advancements in inhalation technology and increased patient demand [2][4] - The concept of "silent zone" in the lungs, referring to small airways that are often overlooked in asthma treatment, is gaining attention as a critical area for intervention [1][3] - The need for innovative drug delivery systems that can effectively target both large and small airways is essential for overcoming current treatment challenges in asthma management [4][6] Market Dynamics - The current diagnosis rate for asthma in China is about 28.5%, with a similar control rate, indicating that over 70% of asthma patients are not effectively managed [4] - The market for allergic asthma drugs is projected to reach 19.6 billion yuan in 2024, reflecting a steady increase due to rising patient numbers and pharmaceutical investments in research and development [4][5] - Inhalation therapies are becoming the mainstream treatment for respiratory diseases, with ultra-fine particle drugs showing a significant increase in lung deposition rates, reaching up to 56% [6][8] Competitive Landscape - Global leaders in the allergic asthma drug market include GlaxoSmithKline and AstraZeneca, while domestic companies like Zhengda Tianqing and Hengrui Medicine are emerging as significant players [5] - The inhalation drug market is dominated by a few key products, with Budesonide leading the market at 5.3 billion yuan, accounting for 23.7% of the inhalation drug market share in China [8] - The market is witnessing increased collaboration and strategic investments, as seen with Baiyang Pharmaceutical's investment in Jikun Pharmaceutical for innovative drug development [11][12] Regulatory and Policy Environment - The "Healthy China 2030" initiative emphasizes the prevention and treatment of respiratory diseases, aiming to reduce mortality rates and enhance healthcare services [7] - The government is expanding insurance coverage for respiratory diseases, which is expected to further stimulate market demand [7] Future Trends - There is a growing focus on targeted therapies for different asthma phenotypes, moving towards personalized treatment plans based on genetic and biomarker assessments [9][10] - The introduction of biologics as adjunct therapies is gaining traction, although they currently cannot replace existing treatment regimens [10][12] - Companies are increasingly looking to align their strategies with China's healthcare policies and demographic trends, particularly in the context of an aging population and rising chronic disease prevalence [13][14]

Investment Rating - The industry investment rating is "Buy" (maintained) [2] Core Viewpoints - The domestic innovative drug industry is entering a turning point in 2025, shifting from capital-driven to profit-driven operations, with ongoing support from fundamentals and policies expected to continue the dual recovery trend in performance and valuation [6][38] - The demand side shows significant certainty advantages, while the supply side is improving in terms of industry and market competition, leading to an overall optimization of the supply-demand structure [6][41] Summary by Sections Market Analysis and Outlook - The innovative drug sector is experiencing a recovery, with key policies supporting market expansion, including the introduction of the first Class B medical insurance directory and ongoing support for innovative drug pricing mechanisms [6][39][40] - Recent performance data shows a median weekly decline of 2.62% among 85 sample innovative drug companies, with notable performers including Yaoke Ankang-B and Shengnuo Pharmaceutical-B [7][18] Clinical Progress and Investment Opportunities - The KRAS G12D clinical progress indicates significant unmet clinical needs in pancreatic cancer, with promising data from Revolution Medicines showing improved efficacy compared to traditional chemotherapy [7][30][36] - The report highlights two main investment lines: 1. Pharma companies transitioning to innovation, with strong performance resilience and a focus on companies like Sanofi Pharmaceutical and Aosaikang [8][41] 2. Biotech companies with potential for overseas product registration, emphasizing the growth of R&D platforms and commercialization [8][41] Performance Metrics - The annual performance from January 1, 2025, to September 13, 2025, shows significant gains, with the Hang Seng Biotech index up 103.30%, A-share biotech up 53.54%, and NASDAQ biotech up 10.57% [10][20]

Investment Rating - The industry investment rating is "Overweight" [1] Core Insights - The report highlights the ongoing global biotechnology revolution, emphasizing its integration into economic and social development to address major challenges such as health, climate change, and food security. The National Development and Reform Commission has issued the "14th Five-Year Plan for Biological Economy Development," indicating a trillion-yuan market potential in the biological economy [3][4]. Market Performance - The synthetic biology index increased by 2.01% to 1218.13 during the week of September 1-5, 2025, outperforming the Shanghai Composite Index by 3.19% and underperforming the ChiNext Index by 0.34% [4][20]. - The top five performing companies in the synthetic biology sector during the same week were: - Haizheng Biomaterials (+17%) - BeiGene (+15%) - Kelun Pharmaceutical (+11%) - Health元 (+9%) - Yuanli Technology (+6%) [21][22]. Company Developments - Fuxiang Pharmaceutical has established a wholly-owned subsidiary in Singapore to expand its microbial protein business, aiming for an annual production capacity of 20,000 tons of microbial protein and 50,000 tons of amino acid water-soluble fertilizer [26]. - Kasei (Taiyuan) Biomaterials Co., Ltd. has announced a project for the annual production of 90,000 tons of bio-based polyamide, with existing production capabilities in bio-based products [26]. - Zhejiang Zhenyuan has officially launched its industrialization base for synthetic biology, which includes a facility for the production of histidine and other bio-based products [29]. - Honeywell has partnered with Syzygy Plasmonics to initiate the world's first electrified biogas-to-sustainable aviation fuel (SAF) project in Uruguay, expected to produce over 350,000 gallons of SAF annually [29][30]. Industry Standards - The national standard GB/T 46256-2025 for bio-based materials and products has been released, which will take effect on March 1, 2026. This standard establishes a comprehensive identity certification system for bio-based materials, promoting industry standardization and regulation [10].

Core Viewpoint - Health元's stock price has experienced fluctuations, with a year-to-date increase of 16.71% but a recent decline of 5.07% over the past five trading days [1] Company Overview - Health元 Pharmaceutical Group Co., Ltd. is located in Nanshan District, Shenzhen, Guangdong Province, and was established on December 18, 1992, with its listing date on June 8, 2001 [1] - The company operates as a comprehensive pharmaceutical enterprise, primarily engaged in the research, development, and production of traditional Chinese medicine, health products, and Western medicine [1] - The revenue composition includes: chemical preparations 47.71%, chemical raw materials and intermediates 31.97%, traditional Chinese medicine preparations 10.28%, diagnostic reagents and equipment 4.74%, health food 3.08%, biological products 1.20%, and others 0.86% [1] Financial Performance - For the first half of 2025, Health元 reported operating revenue of 7.898 billion yuan, a year-on-year decrease of 4.08%, while net profit attributable to shareholders increased by 1.10% to 785 million yuan [2] - Since its A-share listing, Health元 has distributed a total of 3.979 billion yuan in dividends, with 1.04 billion yuan distributed in the last three years [3] Shareholder Information - As of June 30, 2025, Health元 had 76,300 shareholders, a decrease of 4.32% from the previous period, with an average of 23,991 circulating shares per person, an increase of 4.52% [2] - The top ten circulating shareholders include Hong Kong Central Clearing Limited as the second-largest shareholder with 68.3785 million shares, an increase of 14.9969 million shares from the previous period [3]